Evidence map›Paper›PMID 24533233›Full record

ArticleCurrent obstetrics and gynecology reports2014

Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.

Jayne Knoff, Benjamin Yang, Chien-Fu Hung, T-C Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current obstetrics and gynecology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jayne KnoffDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
Benjamin YangDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA ; Department of Oncology, Johns Hopkins University, Baltimore, MD 21205, USA.
T-C WuDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA ; Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD 21205, USA ; Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD 21205, USA ; Department of Oncology, Johns Hopkins University, Baltimore, MD 21205, USA.
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425
6 · The paper itself

Abstract

It is well known that human papillomavirus (HPV) is the causative agent of cervical cancer. The integration of HPV genes into the host genome causes the upregulation of E6 and E7 oncogenes. E6 and E7 proteins inactivate and degrade tumor suppressors p53 and retinoblastoma, respectively, leading to malignant progression. HPV E6 and E7 antigens are ideal targets for the development of therapies for cervical cancer and precursor lesions because they are constitutively expressed in infected cells and malignant tumors but not in normal cells and they are essential for cell immortalization and transformation. Immunotherapies are being developed to target E6/E7 by eliciting antigen-specific immune responses. siRNA technologies target E6/E7 by modulating the expression of the oncoproteins. Proteasome inhibitors and histone deacetylase inhibitors are being developed to indirectly target E6/E7 by interfering with their oncogenic activities. The ultimate goal for HPV-targeted therapies is the progression through clinical trials to commercialization.

Indexed as

cervical cancergynecological cancerhistone deacetylase inhibitorHPV-targeted therapieshuman papillomavirusproteasome inhibitorsiRNAtargeted therapyvaccine

Identifiers

PMID24533233
PMCPMC3921905
OpenAlexW1981543156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.